Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis. [electronic resource]
Producer: 20190612Description: 21-25 p. digitalISSN:- 2468-2942
- Antineoplastic Agents -- therapeutic use
- Cost-Benefit Analysis
- Drug Administration Schedule
- Febrile Neutropenia -- chemically induced
- Female
- Filgrastim -- administration & dosage
- Humans
- Ovarian Neoplasms -- drug therapy
- Polyethylene Glycols -- administration & dosage
- Primary Prevention
- Quality of Life
- Quality-Adjusted Life Years
- Risk Factors
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.